Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADVM Adverum Biotechnologies Inc
- Stocks
- Healthcare
- NASDAQ: ADVM
Price (delayed)
$2.25
Market cap
$47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.43
Enterprise value
$81.82M
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate,
Highlights
ADVM's EPS is up by 32% YoY but it is down by 12% QoQ
Adverum Biotechnologies's equity has shrunk by 86% YoY and by 63% QoQ
The quick ratio has plunged by 63% YoY and by 39% from the previous quarter
Key stats
What are the main financial stats of ADVM
Market
Valuations
Earnings
Shares outstanding
20.89M
Market cap
$47M
Enterprise value
$81.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.77
Price to sales (P/S)
47.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
81.82
Revenue
$1M
Gross profit
$1M
Operating income
-$160.54M
Net income
-$153.16M
EBIT
-$153.16M
EBITDA
-$128.8M
Free cash flow
-$112.51M
Per share
Balance sheet
Liquidity
EPS
-$7.43
EPS diluted
-$7.43
Free cash flow per share
-$5.37
Book value per share
$1.27
Revenue per share
$0.05
TBVPS
$6.57
Total assets
$137.65M
Total liabilities
$111.23M
Debt
$85.95M
Equity
$26.42M
Working capital
$64.38M
Debt to equity
3.25
Current ratio
3.57
Quick ratio
3.39
Net debt/EBITDA
-0.27
Margins
Efficiency
Dividend
EBITDA margin
-12,880.4%
Gross margin
100%
Net margin
-15,315.9%
Operating margin
-16,054.1%
Return on assets
-76%
Return on equity
-149.7%
Return on invested capital
-91.8%
Return on capital employed
-136.1%
Return on sales
-15,315.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADVM stock price
How has the Adverum Biotechnologies stock price performed over time
Intraday
-1.75%
1 week
-8.54%
1 month
-10%
1 year
-65.7%
YTD
-51.82%
QTD
-48.51%
Financial performance
How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$160.54M
Net income
-$153.16M
Gross margin
100%
Net margin
-15,315.9%
Adverum Biotechnologies's net income has decreased by 27% YoY and by 17% QoQ
ADVM's operating income is down by 26% YoY and by 15% from the previous quarter
Adverum Biotechnologies's net margin has decreased by 17% QoQ
Adverum Biotechnologies's operating margin has decreased by 15% QoQ
Price vs fundamentals
How does ADVM's price correlate with its fundamentals
Growth
What is Adverum Biotechnologies's growth rate over time
Valuation
What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
1.77
P/S
47.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
81.82
ADVM's EPS is up by 32% YoY but it is down by 12% QoQ
Adverum Biotechnologies's equity has shrunk by 86% YoY and by 63% QoQ
The price to book (P/B) is 26% higher than the 5-year quarterly average of 1.4 and 4.1% higher than the last 4 quarters average of 1.7
Efficiency
How efficient is Adverum Biotechnologies business performance
Adverum Biotechnologies's return on equity has shrunk by 61% QoQ and by 50% YoY
The company's return on assets fell by 36% YoY and by 36% QoQ
Adverum Biotechnologies's return on invested capital has decreased by 19% QoQ and by 6% YoY
ADVM's ROS is down by 17% QoQ
Dividends
What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADVM.
Financial health
How did Adverum Biotechnologies financials performed over time
The total assets is 24% greater than the total liabilities
The quick ratio has plunged by 63% YoY and by 39% from the previous quarter
ADVM's current ratio has dropped by 61% year-on-year and by 38% since the previous quarter
Adverum Biotechnologies's debt to equity has surged by 166% QoQ
Adverum Biotechnologies's equity has shrunk by 86% YoY and by 63% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.